The study aimed to investigate the efficacy and safety of RC48 in HR-NMIBC as a novel treatment strategy. Researchers noticed that RC48, alone or with tislelizumab, demonstrates promising efficacy and manageable AE’s in patients with NMIBC. RC48 is a novel antibody-drug conjugate that targets the Her2 protein and has exhibited promising efficacy in […]...
AUA 2024
Coverage of American Urological Association Annual Meeting
May 03
-May 06, 2024